Press coverage about MiMedx Group (NASDAQ:MDXG) has trended somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MiMedx Group earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 43.9452030799754 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- One Stock with Higher Beta value: MiMedx Group, Inc. (MDXG) – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Comprehensive Stock Analysis – MiMedx Group Inc (NASDAQ: MDXG) – Alpha Beta Stock (alphabetastock.com)
- RSI Alert: MiMedx Group, Inc. (MDXG) stock could lead to an upward move – Nasdaq Chronicle (nasdaqchronicle.com)
- INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of MiMedx Group Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 25, 2018 – MDXG (finance.yahoo.com)
- The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of MiMedx Group Inc. Shareholders and a Lead Plaintiff Deadline of April 25, 2018 (finance.yahoo.com)
MDXG stock opened at $7.27 on Wednesday. The firm has a market cap of $801.67, a PE ratio of 23.45, a price-to-earnings-growth ratio of 0.94 and a beta of 1.65. MiMedx Group has a 1 year low of $6.05 and a 1 year high of $18.25.
A number of brokerages have weighed in on MDXG. BidaskClub downgraded shares of MiMedx Group from a “hold” rating to a “sell” rating in a research report on Friday, March 16th. Needham & Company LLC reiterated a “hold” rating on shares of MiMedx Group in a research report on Thursday, March 15th. ValuEngine downgraded shares of MiMedx Group from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Craig Hallum reiterated a “buy” rating on shares of MiMedx Group in a research report on Tuesday, February 27th. Finally, Lake Street Capital downgraded shares of MiMedx Group from a “buy” rating to a “hold” rating and set a $9.00 price objective for the company. in a research report on Friday, February 23rd. Four research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $14.75.
WARNING: This news story was originally published by Week Herald and is owned by of Week Herald. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://weekherald.com/2018/03/21/mimedx-group-mdxg-receives-news-impact-rating-of-0-15.html.
About MiMedx Group
MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.